Cite
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
MLA
D’Silva, Arlene M., et al. “Onasemnogene Abeparvovec in Spinal Muscular Atrophy: An Australian Experience of Safety and Efficacy.” Annals of Clinical & Translational Neurology, vol. 9, no. 3, Mar. 2022, pp. 339–50. EBSCOhost, https://doi.org/10.1002/acn3.51519.
APA
D’Silva, A. M., Holland, S., Kariyawasam, D., Herbert, K., Barclay, P., Cairns, A., MacLennan, S. C., Ryan, M. M., Sampaio, H., Smith, N., Woodcock, I. R., Yiu, E. M., Alexander, I. E., & Farrar, M. A. (2022). Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Annals of Clinical & Translational Neurology, 9(3), 339–350. https://doi.org/10.1002/acn3.51519
Chicago
D’Silva, Arlene M., Sandra Holland, Didu Kariyawasam, Karen Herbert, Peter Barclay, Anita Cairns, Suzanna C. MacLennan, et al. 2022. “Onasemnogene Abeparvovec in Spinal Muscular Atrophy: An Australian Experience of Safety and Efficacy.” Annals of Clinical & Translational Neurology 9 (3): 339–50. doi:10.1002/acn3.51519.